Literature DB >> 1864725

Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.

O A Gansow1.   

Abstract

Monoclonal antibodies (mAbs) radiolabeled by use of metal chelators are being investigated in the laboratory for use in clinical trials. 111In is presently employed for diagnostic scintigraphy, but its applications are limited by substantive and persistant uptake of radiometal in the liver. Much current research is focused on performing cancer therapy with 90Y and 212Bi chelate-linked mAbs. This report chronicles the development and evaluation of chelating agents for 111In-radioimmunoimaging and 90Y- and 212Bi-radioimmunotherapy.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1864725     DOI： 10.1016/0883-2897(91)90063-q

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN： 0883-2897


  9 in total

Review 1.  Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

Authors:  J F Chatal; P Peltier; M Bardiès; A Chétanneau; P Thedrez; A Faivre-Chauvet; J F Gestin
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

3.  Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.

Authors:  Robert M Sharkey; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

4.  A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.

Authors:  Lin Li; James Bading; Paul J Yazaki; Amitkumar H Ahuja; Desiree Crow; David Colcher; Lawrence E Williams; Jeffrey Y C Wong; Andrew Raubitschek; John E Shively
Journal:  Bioconjug Chem       Date:  2007-11-08       Impact factor: 4.774

5.  Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.

Authors:  Shuping Dou; Yuzhen Wang; Bruce Barton; Ling Chen; Mary Rusckowski; Leonard D Shultz; Dale L Greiner; Guozheng Liu
Journal:  Nucl Med Biol       Date:  2013-10-09       Impact factor: 2.408

6.  Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Jane N Winter; David J Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W Rademaker; Bing Bing Weitner; Stephanie F Williams; Martin S Tallman; Ivana Micallef; Jayesh Mehta; Seema Singhal; Andrew M Evens; Michael Zimmer; Arturo Molina; Christine A White; Leo I Gordon
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 7.  Multimodality imaging of the HER-kinase axis in cancer.

Authors:  Weibo Cai; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

8.  Immunolymphoscintigraphy for metastatic sentinel nodes: test of a model.

Authors:  A H Chakera; B S Nielsen; J Madsen; J Romer; P E G Kristjansen; I Buch; T Binderup; C Ingvar; A Nalla; A Kjaer; B Hesse
Journal:  Int J Mol Imaging       Date:  2011-04-28

9.  Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.

Authors:  Kelvin S H Loke; Ajit K Padhy; David C E Ng; Anthony S W Goh; Chaitanya Divgi
Journal:  World J Nucl Med       Date:  2011-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.